SCHEMBL4620997

SCHEMBL4620997

O=C(S)c1cccnc1S

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
TDP1 Q9NUW8 1/20 0.47
ALDH1A1 P00352 4/20 0.45
MAPT P10636 3/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CYP3A4 P08684 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
BLM P54132 1/20 0.45
AGER Q15109 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
NAPRT Q6XQN6 3/20 0.44
LMNA P02545 3/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PARP1 P09874 1/20 0.40
P2RX7 Q99572 1/20 0.39
DHODH Q02127 1/20 0.38
MYC P01106 1/20 0.37
PRKCI P41743 2/20 0.36
CES2 O00748 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2-Mercaptonicotinic Acid SCHEMBL29382089 0.83 KDM4E (0.63) KDM4ETDP1ALDH1A1MAPTL3MBTL1
2-Mercaptonicotinic Acid SCHEMBL261186 0.83 KDM4E (0.63) KDM4ETDP1ALDH1A1MAPTL3MBTL1
2-Mercaptonicotinic Acid SCHEMBL29105774 0.81 KDM4E (0.61) KDM4ETDP1ALDH1A1MAPTL3MBTL1
SCHEMBL21995771 0.81 SMN1; SMN2 (0.47) KDM4ETDP1ALDH1A1MAPTL3MBTL1
SCHEMBL19017652 0.81 SMN1; SMN2 (0.47) KDM4ETDP1ALDH1A1MAPTL3MBTL1
SCHEMBL1326787 0.81 PARP1 (0.56) KDM4ETDP1ALDH1A1MAPTL3MBTL1
2-Mercaptonicotinic Acid SCHEMBL29181672 0.81 KDM4E (0.61) KDM4ETDP1ALDH1A1MAPTL3MBTL1
2-Mercaptonicotinic Acid SCHEMBL30605292 0.81 KDM4E (0.61) KDM4ETDP1ALDH1A1MAPTL3MBTL1
SCHEMBL27951997 0.81 KDM4E (0.45) KDM4ETDP1ALDH1A1MAPTL3MBTL1
SCHEMBL5184012 0.80 KDM4E (0.57) KDM4ETDP1ALDH1A1MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080193397-A1 Use of Peroxide Decomposers Method For the Treatment of a Material Other Than the Human Body BASF AKTIENGESELLSCAFT (DE) 2008-08-14 US disclosed
EP-1881817-A2 USE OF PEROXIDE DECOMPOSERS IN COSMETIC AND PHARMACEUTICAL AGENTS FOR TREATING SKIN BASF AKTIENGESELLSCHAFT (DE) 2008-01-30 EP disclosed
WO-2006122721-A2 USE OF PEROXIDE DECOMPOSERS IN COSMETIC AND PHARMACEUTICAL AGENTS FOR TREATING SKIN BASF AKTIENGESELLSCHAFT (DE) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080193397-A1 Use of Peroxide Decomposers Method For the Treatment of a Material Other Than the Human Body GPX4, LPO, GPX1 KDM4E 2807/4885TDP1 533/4885ALDH1A1 569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.